EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis

Isabella Christina Amaral de Lara, Mariana Rachas Reis, Alícia Batista de Almeida Barbosa, Francisco Cezar Aquino de Moraes, Maria Clara Leão de Andrade Neves, Maria Eugenia Pedruzzi Dalmaschio, Lilianne Rodrigues Fernandes

Journal of Food Allergy · 01.07.2026 · 8 (1) · 22-30

DOI: 10.2500/jfa.2026.8.260001 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Food Allergy, erschienen am 01.07.2026. Verfasst von Isabella Christina Amaral de Lara und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current management strategies for peanut allergy involve shared decision-making and several treatment modalities, including immunotherapy. Sublingual immunotherapy (SLIT) is emerging as a potential safer option for peanut immunotherapy.

Objective

We sought to systematically evaluate the efficacy and safety of SLIT for peanut allergy management in comparison with placebo.

Methods

We searched four data bases for randomized controlled trials (RCT). Outcomes of interest were tolerated dose during double-blind placebo controlled food challenge (DBPCFC), immunoglobulin E (IgE) and IgG4 levels, skin-prick test (SPT) and adverse events (AE).

Results

We identified three RCTs, comprising 108 patients with peanut allergy. There was a statistically significant increase in IgG4 levels (standardized mean difference [SMD] 0.56 kU/L [95% confidence interval [CI], 0.17-0.96 kU/L) and oropharyngeal AE (risk ratio [RR] 19.90 [95% CI, 4.00-99.07]) in the SLIT group. No significant difference in DBPCFC after treatment (mean difference [MD] 1612.90 mg [95% CI, −949.93 to 4175.74 mg]) and IgE levels (SMD −0.54 [95% CI, −1.46 to 0.37]) was observed. Respiratory, skin, and gastrointestinal AE incidences in the SLIT group were comparable with the placebo group (RR 2.11 [95% CI, 0.18-25.18], RR 1.57 [95% CI, 0.06-39.13], RR 3.51 [95% CI, 0.30-40.87], respectively). In children, SLIT showed improvement in DBPCFC results (MD 2529.57 mg [95% CI, 347.39-4711.75]) and SPT (MD −8.60 mm [95% CI, −11.13 to −6.07 mm).

Conclusion

Our meta-analysis demonstrated peanut SLIT safety and demonstrated a desensitization potential in children.

Zitieren

APA

Lara, I. C. A. D., Reis, M. R., Barbosa, A. B. D. A., Moraes, F. C. A. D., Neves, M. C. L. D. A., Dalmaschio, M. E. P., & Fernandes, L. R. (2026). Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis. Journal of Food Allergy, 8(1), 22-30. https://doi.org/10.2500/jfa.2026.8.260001

Vancouver

Lara ICAD, Reis MR, Barbosa ABDA, Moraes FCAD, Neves MCLDA, Dalmaschio MEP, et al. Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis. Journal of Food Allergy. 2026;8(1):22-30. doi:10.2500/jfa.2026.8.260001

BibTeX
@article{Lara2026,
  author = {Lara, Isabella Christina Amaral de and Reis, Mariana Rachas and Barbosa, Alícia Batista de Almeida and Moraes, Francisco Cezar Aquino de and Neves, Maria Clara Leão de Andrade and Dalmaschio, Maria Eugenia Pedruzzi and Fernandes, Lilianne Rodrigues},
  title = {Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis},
  journal = {Journal of Food Allergy},
  year = {2026},
  volume = {8},
  number = {1},
  pages = {22--30},
  doi = {10.2500/jfa.2026.8.260001}
}
Kostenlos starten →